Wall Street analyst estimates for Intuitive Surgical, Inc. (ISRG): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets.
Consensus price target
$485.44 (+8 % vs price $448.76)
between $357.44 and $558.00 · 11 targets published in the last quarter
Closing price, Oct 29
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $11.9B | $11.6B – $12.0B | $11.23 | 16 |
| 2027E | $13.3B | $13.0B – $13.7B | $12.46 | 16 |
| 2028E | $15.0B | $13.7B – $15.7B | $14.03 | 11 |
Figures in USD · consensus as of October 29, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 40 |
| Hold | 12 |
| Sell | 5 |
| Strong Sell | 0 |
| Total analysts | 57 |
| Avg rating (−2 sell to +2 buy) | 0.61 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-01-28 | $2.97 | ||
| 2026-10-20 | $3.00 | $2.65 | +13.2% |
| 2026-07-16 | $2.80 | $2.51 | +11.6% |
| 2026-04-21 | $2.80 | $2.51 | +11.6% |
| 2026-01-22 | $2.53 | $2.27 | +11.5% |
| 2025-10-21 | $2.40 | $1.99 | +20.6% |
| 2025-07-22 | $2.19 | $1.93 | +13.5% |
| 2025-04-22 | $1.81 | $1.74 | +4.0% |
Valuation Ratios
| P/E Ratio | 53.87 |
| Price / Book | 9.70 |
| EV / EBITDA | 36.73 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $51.7M | $72.0M | $91.7M | $138.8M | $227.3M | $372.7M | $600.8M | $874.9M | $1.05B | $1.41B | $1.76B | $2.18B | $2.27B | $2.13B | $2.38B | $2.70B | $3.13B | $3.72B | $4.48B | $4.36B | $5.71B | $6.22B | $7.12B | $8.35B | $10.06B |
| Cost of Revenue | $28.2M | $34.6M | $47.6M | $50.8M | $73.8M | $124.8M | $186.5M | $254.1M | $301.1M | $383.0M | $483.5M | $608.5M | $670.9M | $717.9M | $806.5M | $814.3M | $934.8M | $1.12B | $1.37B | $1.50B | $1.75B | $2.03B | $2.39B | $2.72B | $3.42B |
| Gross Profit | $23.5M | $37.4M | $44.0M | $88.0M | $153.6M | $247.8M | $414.3M | $620.8M | $751.1M | $1.03B | $1.27B | $1.57B | $1.59B | $1.41B | $1.58B | $1.89B | $2.19B | $2.60B | $3.11B | $2.86B | $3.96B | $4.20B | $4.73B | $5.63B | $6.64B |
| Research & Development | $13.9M | $16.8M | $16.2M | $17.8M | $17.4M | $29.8M | $48.9M | $79.4M | $95.1M | $116.0M | $140.2M | $170.0M | $167.7M | $178.0M | $197.4M | $239.6M | $328.6M | $418.1M | $557.3M | $595.1M | $671.0M | $879.0M | $998.8M | $1.15B | $1.31B |
| Selling, General & Admin | $30.0M | $40.9M | $39.7M | $49.0M | $67.4M | $110.7M | $158.7M | $230.6M | $278.5M | $358.8M | $438.8M | $522.2M | $574.0M | $691.0M | $640.5M | $705.3M | $810.9M | $986.6M | $1.18B | $1.22B | $1.47B | $1.74B | $1.96B | $2.14B | $2.38B |
| Operating Expenses | $43.8M | $57.7M | $55.9M | $66.8M | $84.8M | $140.5M | $207.5M | $309.9M | $373.6M | $474.8M | $579.0M | $692.2M | $741.7M | $869.0M | $837.9M | $944.9M | $1.14B | $1.40B | $1.74B | $1.81B | $2.14B | $2.62B | $2.96B | $3.29B | $3.70B |
| Operating Income | -$20.4M | -$20.2M | -$11.9M | $21.2M | $68.8M | $107.4M | $206.7M | $310.8M | $377.4M | $555.2M | $694.8M | $878.1M | $852.5M | $544.8M | $740.0M | $945.2M | $1.05B | $1.20B | $1.37B | $1.05B | $1.82B | $1.58B | $1.77B | $2.35B | $2.95B |
| EBITDA | -$15.7M | -$15.7M | -$1.3M | $28.3M | $75.5M | $142.6M | $219.8M | $335.9M | $412.0M | $595.6M | $741.3M | $935.9M | $919.8M | $623.4M | $829.5M | $1.04B | $1.16B | $1.32B | $1.58B | $1.33B | $2.20B | $1.97B | $2.41B | $3.14B | $3.99B |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $15.8M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$20.3M | -$18.4M | -$9.6M | $24.2M | $73.8M | $120.1M | $237.2M | $335.2M | $396.1M | $572.3M | $709.7M | $893.9M | $870.9M | $549.0M | $758.5M | $980.8M | $1.10B | $1.28B | $1.50B | $1.21B | $1.89B | $1.61B | $1.96B | $2.67B | $3.31B |
| Income Tax | -$3.7M | 0 | 0 | $726,000 | -$20.3M | $48.1M | $92.7M | $130.9M | $163.5M | $190.5M | $214.6M | $237.3M | $199.9M | $130.2M | $169.7M | $244.9M | $436.5M | $154.5M | $120.4M | $140.2M | $162.2M | $262.4M | $141.6M | $336.3M | $434.8M |
| Net Income | -$16.7M | -$18.4M | -$9.6M | $23.5M | $94.1M | $72.0M | $144.5M | $204.3M | $232.6M | $381.8M | $495.1M | $656.6M | $671.0M | $418.8M | $588.8M | $735.9M | $660.0M | $1.13B | $1.38B | $1.06B | $1.70B | $1.32B | $1.80B | $2.32B | $2.86B |
| EPS | $-0.10 | $-0.11 | $-0.05 | $0.08 | $0.30 | $0.22 | $0.42 | $0.58 | $0.67 | $1.08 | $1.40 | $1.83 | $1.86 | $1.26 | $1.76 | $2.13 | $1.97 | $3.31 | $3.98 | $3.02 | $4.79 | $3.72 | $5.12 | $6.54 | $8.00 |
| EPS (Diluted) | $-0.10 | $-0.11 | $-0.05 | $0.07 | $0.28 | $0.21 | $0.41 | $0.57 | $0.66 | $1.05 | $1.37 | $1.78 | $1.86 | $1.23 | $1.73 | $2.08 | $1.89 | $3.16 | $3.85 | $2.94 | $4.66 | $3.65 | $5.03 | $6.42 | $7.87 |
| Shares Outstanding (Diluted) | 161.2 M | 164.1 M | 212.6 M | 314.8 M | 337.4 M | 342.8 M | 351.2 M | 359.5 M | 352.8 M | 362.7 M | 361.8 M | 369.9 M | 361.0 M | 339.3 M | 341.1 M | 353.7 M | 348.9 M | 356.4 M | 358.5 M | 360.9 M | 365.8 M | 362.0 M | 357.4 M | 362.0 M | 362.7 M |
Price
| Price | $448.76 (closing price, October 29, 2026) |
| Market Cap | $158.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: SYK · SNN · 0R29.L · 0R19.L · BDX · RMD · 0KW4.L · WST
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of ISRG: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks